MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD)

As reported by seekingalpha.com

As you know, MannKind ( MNKD ) has just seen the approval of Afrezza by the FDA. Now, the way I see it is that this is a pretty meaningful expansion of an alrea...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on seekingalpha.com ↗

Market Samachar is a news aggregator. This article was originally published by seekingalpha.com. Tap the button above to read the full story on their site.

INDIAN Global Market: Japan's Nikkei surges past 68,000 for first time as AI stocks lead rally Markets-Economic Times
COMPANIES Concord Biotech jumps 8% on USFDA nod for Mycophenolate Mofetil oral suspension Stocks-Markets-Economic Times
INDIAN 'Wait out IT, buy pharma and defence'; Ajay Bagga's 3-sector playbook for 2026 Markets-Economic Times
COMPANIES TCS, Infosys, other IT stocks crash up to 7% after 3-day rally. What top brokerages are saying? Stocks-Markets-Economic Times
COMPANIES NHPC shares jump 5% as OFS worth Rs 4,300 crore opens for retail investors. Here's all you need to know Stocks-Markets-Economic Times
INDIAN IT sector entering a new growth phase, says Sandip Agarwal; sees strong earnings upside ahead Markets-Economic Times
INDIAN Fed's Hammack signals rate hike may be needed soon as inflation risks intensify Markets-Economic Times
INDIAN From $120 to $95: Crude oil prices surged 70% during the US-Iran war. Can Brent crude price drop to $80 mint - markets

MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD)

More from Market Samachar